#Global Trends – Page 5 – HEALTHCARE INSIGHTS

Key Development Global non-clinical research and biologics testing provider Charles River Laboratories International, Inc. (NYSE: CRL) and Taiwan-based vaccine developer... Read more

Tag: #Global Trends

Precision Oncology Milestone: US FDA Approves Revolution Medicines’ Rasonque® (Daraxonrasib) as First-in-Class RAS(ON) Multiselective Inhibitor for Metastatic Pancreatic Cancer, Doubling Overall Survival to 13.2 Months

FDA EXPANDS IMAAVY: J&J TURNS FCRN BLOCKADE INTO A RARE AUTOIMMUNE GROWTH PLATFORM

ROCHE–ELI LILLY BRINGS ALZHEIMER’S BLOOD TESTING INTO MAINSTREAM DIAGNOSTIC INFRASTRUCTURE: COMPETITION IS SHIFTING FROM DRUGS TO ECOSYSTEMS

Non-Incretin Cardiometabolic Licensing: Genentech Pays $190 Million Upfront in $2.3 Billion Global License Agreement with Hanmi Pharm for Muscle-Preserving Obesity Peptide HM17321

Biologics & ADC CDMO Consolidation: Piramal Pharma Acquires Controlling 74% Stake in Yapan Bio for $7.95 Million – Accelerating Integrated ADCelerate™ Bioconjugation Platform

European CDMO Infrastructure Expansion: SK pharmteco Completes Major Manufacturing Expansions in Swords, Ireland – Boosting Small-Molecule API, High-Potency API (HPAPI), and ADC Payload Capabilities

AI-Driven Biologics Engineering: Bristol Myers Squibb and Chai Discovery Partner to Accelerate De Novo Therapeutic Antibody Candidate Identification

Advanced Biologics Testing & CMC Validation: Charles River Laboratories and Medigen Partner to Validate Virus Seed Bank for Next-Generation Multivalent Enterovirus Vaccine

Mass Tort Litigation Defense: Abbott Agrees to $670 Million Settlement to Resolve 2,000 Preterm Infant Formula Necrotizing Enterocolitis (NEC) Claims

Facebook

Map

Online Members